<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01305733</url>
  </required_header>
  <id_info>
    <org_study_id>Coxa - LIA</org_study_id>
    <nct_id>NCT01305733</nct_id>
  </id_info>
  <brief_title>Local Infiltration Analgesia During Total Knee Arthroplasty</brief_title>
  <acronym>LIA</acronym>
  <official_title>Local Infiltration Analgesia During Total Knee Arthroplasty - Reduced Opiate Consumption and Faster Mobilisation Postoperatively - Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coxa, Hospital for Joint Replacement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coxa, Hospital for Joint Replacement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate whether local infiltration analgesia (LIA) will reduce
      oxycodone consumption during the first 48 postoperative hours in patients undergoing total
      knee arthroplasty (TKA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of LIA is to gain an effective and safe pain control during the first postoperative
      days. The study is a single-center, randomized controlled trial, which will be performed in
      Coxa Hospital for Joint Replacement in Tampere, Finland. The injectant mixture consists of
      150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline with occasional
      variations if the patient is unusually small, very elderly, infirm or has a history of
      significant intolerance to analgesics or anesthetic agents. The RKA mixture is diluted with
      normal saline. Total volume of the solution is 100 ml depending on the size of the wound. The
      normal saline injection are used in the control group in the same manner than in the RKA
      group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>oxycodone consumption during the first 48 postoperative hours</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>functional outcome after TKA</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>local infiltration analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The normal saline injection are used in the control group in the same manner than in the RKA group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline</intervention_name>
    <description>The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline</description>
    <arm_group_label>local infiltration analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline injection</intervention_name>
    <description>saline</description>
    <arm_group_label>saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring primary TKA for primary OA

          -  Patients aged 75 years or less

          -  Patients suitable for all applicable devices

        Exclusion Criteria:

          -  Rheumatoid arthritis or other inflammatory diseases

          -  Patients requiring bone grafting during surgery

          -  Unwilling to provide informed consent

          -  BMI &gt; 35

          -  ASA &gt; 3

          -  Renal dysfunction

          -  Allergic to ASA

          -  Previous high tibial osteotomy or previous osteosynthesis

          -  &gt; 15 degrees varus / valgus malalignment

          -  Physical, emotional or neurological conditions which would comprise the patient´s
             compliance with postoperative rehabilitation and follow-up (e.g. drug or alcohol
             abuse, serious mental illness, general neurological conditions such as Parkinson, MS,
             etc.)

          -  Known sensitivity to materials in the devices
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antti Eskelinen, M.D., Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Coxa, Hospital for Joint Replacement</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mika Niemeläinen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coxa, Hospital for Joint Replacement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coxa - hospital for joint replacement</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33560</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COXA</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33560</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2011</study_first_submitted>
  <study_first_submitted_qc>February 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2011</study_first_posted>
  <last_update_submitted>May 8, 2012</last_update_submitted>
  <last_update_submitted_qc>May 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coxa, Hospital for Joint Replacement</investigator_affiliation>
    <investigator_full_name>Mika Niemeläinen</investigator_full_name>
    <investigator_title>orthopaedic surgeon</investigator_title>
  </responsible_party>
  <keyword>Pain relief</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 8, 2015</submitted>
    <returned>October 7, 2015</returned>
    <submitted>July 24, 2017</submitted>
    <returned>February 2, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

